Year Founded
2021
Ownership
Private
Employees
~50
Therapeutic Areas
OtherNeurology
Stage
Phase 2
Modalities
Cancer immunotherapyProtein therapeutics

ADvantage Therapeutics General Information

AD04™ demonstrated statistically significant slower cognitive decline and reduced hippocampal shrinkage in early Alzheimer's Disease patients during Phase 2 trials. It was safe and well-tolerated with no evidence of autoimmunity or toxicity.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Miami, Florida
United States

Drug Pipeline

AD04
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to ADvantage Therapeutics's pipeline data

Book a demo

Key Partnerships

Longevitytech.fund

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

ADvantage Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJul 12, 2023$10.2MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view ADvantage Therapeutics's complete valuation and funding history, request access »

ADvantage Therapeutics Investors

Longevitytech.fund
Investor Type: Venture Capital
Holding: Minority